Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNA-lipoplex vaccine
- Development stage
- Unknown
- Lead developer
- Ahvaz Jundishapur University of Medical Sciences
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
The RNA-lipoplex vaccine is an investigational mRNA-based cancer immunotherapy developed by Ahvaz Jundishapur University of Medical Sciences in Iran. It is formulated as messenger RNA sequences encapsulated in a lipoplex (RNA-liposome) delivery system designed for intravenous administration. The vaccine targets three key prostate cancer-associated tumor antigens: prostate-specific membrane antigen (PSMA), six-transmembrane epithelial antigen of the prostate 1 (STEAP1), and prostatic acid phosphatase (PAP). By delivering these antigen-encoding mRNAs, the vaccine aims to stimulate the patient's immune system, particularly activating cytotoxic T-cells to recognize and destroy prostate cancer cells. It has been evaluated in a completed Phase I clinical trial in Iran to assess its safety, tolerability, immunogenicity, and preliminary antitumor activity in patients with prostate cancer.
- Other names
- RNA-lipoplex vaccine against prostate cancerRNA-lipoplex prostate cancer vaccineRNA-liposome prostate cancer vaccine
02
Targets
STEAP1 (Six-transmembrane epithelial antigen of prostate 1)PAP (Prostatic acid phosphatase)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on RNA-lipoplex vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA-lipoplex vaccine.